Cheng Lai

Title: Cheng Lai - Innovator in Healthcare Solutions

Introduction

Cheng Lai is an accomplished inventor based in Lexington, MA (US). He currently works at Novo Nordisk Healthcare AG, where he focuses on developing innovative healthcare solutions. Despite having no granted patents, his contributions to the field are noteworthy.

Latest Patent Applications

Cheng Lai has filed several significant patent applications, including:

1. **Methods and Compositions for Inhibiting Expression of LDHA** - This disclosure relates to oligonucleotides, compositions, and methods useful for reducing LDHA expression, particularly in hepatocytes.

2. **Compositions and Methods for Inhibiting GYS2 Expression** - This disclosure relates to oligonucleotides, compositions, and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.

Conclusion

Cheng Lai is a dedicated inventor whose work at Novo Nordisk Healthcare AG focuses on innovative methods to address critical healthcare challenges. His latest patent applications reflect his commitment to advancing medical science and improving patient outcomes.